英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
994103查看　994103　在百度字典中的解释百度英翻中〔查看〕
994103查看　994103　在Google字典中的解释Google英翻中〔查看〕
994103查看　994103　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Exciting Breakthrough in Hair Loss Treatment: GT20029 Emerges as a . . .
    As we approach the end of 2025, advancements like GT20029 remind us that hope is on the horizon for millions affected by hair thinning In this article, I’ll break down what GT20029 is, how it works, its recent trial outcomes, how it stacks up against current treatments, and what this means for you as a patient Let’s dive in!
  • First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy . . .
    GT20029 targets AR protein degradation, offering a novel mechanism for AGA treatment, distinct from existing therapies like minoxidil and finasteride Phase 2 trial results showed significant hair density and shaft caliber improvements, especially with the 1 0% BIW dose, compared to placebo
  • Kintor Pharmaceutical Phase 3 Trial Results for KX-826 and GT20029
    Kintor Pharma (China)'s hair loss trials are for two androgen receptor (AR) targeting products: A degrader (GT20029) and an antagonist (KX-826) Pyrilutamide
  • Anyone else just waiting until the real pyrilutamide and then GT20029 . . .
    Anyone else just waiting until the real pyrilutamide and then GT20029? I'm not about to take fin and possibly wreck my hormones But pyrilutamide is still probably 3 years away from the chinese market I also don't believe the stuff that's in the grey market is real, so no comment on the efficacy of those Just biding my time until then
  • GT-20029 - Wikipedia
    The company announced that the investigational new drug (IND) GT20029 for androgenetic alopecia and acne vulgaris indications was accepted by the National Medical Products Administration (NMPA) of China on February 2, 2021
  • Checking your browser - reCAPTCHA - PubMed
    Checking your browser before accessing pubmed ncbi nlm nih gov Click here if you are not automatically redirected after 5 seconds
  • Kintor Advances With GT20029 Clinical Trials for Hair Loss
    GT20029 is a new topical androgen receptor degrader medication developed by Kintor Pharmaceutical Ltd for the treatment of pattern hair loss (androgenetic alopecia) and acne vulgaris
  • Kintor Pharma Announces Positive Top-line U. S. Phase I Trial Results of . . .
    GT20029 is a topical AR degrader developed by Kintor Pharma’s PROTAC platform The China National Medical Products Administration (NMPA) and the U S Food and Drug Administration (FDA) cleared GT20029's clinical trial applications for treating AGA and acne in April 2021 and July 2021, respectively
  • Kintor Releases Phase 2 Trial Results for GT20029
    What is GT20029? GT20029 is a PROTAC that targets androgen receptor (AR) proteins for degradation The PROTAC platform used in GT20029 consists of three components: a recruiting element that binds to the AR protein, an E3 ubiquitin ligase recruiting element, and a linker that connects the two
  • To Evaluate the Efficacy and Safety of GT20029 Solution in the . . .
    The study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of GT20029 solution GT20029 is a new investigational androgen receptor (AR) degrader for the treatment of androgenetic alopecia





中文字典-英文字典  2005-2009